NASDAQ:PODD Insulet (PODD) Stock Price, News & Analysis → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free PODD Stock Alerts $166.26 -6.45 (-3.73%) (As of 04/17/2024 ET) Add Compare Share Share Today's Range$165.10▼$173.7450-Day Range$163.25▼$197.1452-Week Range$125.82▼$335.91Volume682,309 shsAverage Volume878,721 shsMarket Capitalization$11.64 billionP/E Ratio57.13Dividend YieldN/APrice Target$243.21 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Insulet alerts: Email Address Insulet MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside46.3% Upside$243.21 Price TargetShort InterestHealthy4.46% of Shares Sold ShortDividend StrengthN/ASustainability-1.20Upright™ Environmental ScoreNews Sentiment1.26Based on 7 Articles This WeekInsider TradingSelling Shares$1.89 M Sold Last QuarterProj. Earnings Growth25.65%From $3.08 to $3.87 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.68 out of 5 starsMedical Sector58th out of 914 stocksSurgical & Medical Instruments Industry10th out of 94 stocks 3.4 Analyst's Opinion Consensus RatingInsulet has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 12 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageInsulet has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.46% of the outstanding shares of Insulet have been sold short.Short Interest Ratio / Days to CoverInsulet has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Insulet has recently increased by 11.43%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInsulet does not currently pay a dividend.Dividend GrowthInsulet does not have a long track record of dividend growth. Previous Next 4.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInsulet has received a 80.74% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Insulin pumps" product. See details.Environmental SustainabilityThe Environmental Impact score for Insulet is -1.20. Previous Next 2.4 News and Social Media Coverage News SentimentInsulet has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Insulet this week, compared to 8 articles on an average week.Search InterestOnly 6 people have searched for PODD on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Insulet to their MarketBeat watchlist in the last 30 days. This is a decrease of -54% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Insulet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,891,338.00 in company stock.Percentage Held by InsidersOnly 0.80% of the stock of Insulet is held by insiders. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Insulet are expected to grow by 25.65% in the coming year, from $3.08 to $3.87 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insulet is 57.13, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 138.89.Price to Earnings Ratio vs. SectorThe P/E ratio of Insulet is 57.13, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 220.86.Price to Earnings Growth RatioInsulet has a PEG Ratio of 3.13. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioInsulet has a P/B Ratio of 15.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Insulet Stock (NASDAQ:PODD)Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.Read More PODD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PODD Stock News HeadlinesApril 15, 2024 | finance.yahoo.comEarnings growth outpaced the impressive 16% CAGR delivered to Insulet (NASDAQ:PODD) shareholders over the last five yearsApril 15, 2024 | investorplace.com7 Stable Stocks for 50% Returns by Early 2025April 17, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.April 13, 2024 | americanbankingnews.comInsulet Co. (NASDAQ:PODD) Given Average Rating of "Moderate Buy" by BrokeragesApril 10, 2024 | finance.yahoo.comInsulet (PODD) Stock Moves -0.34%: What You Should KnowApril 4, 2024 | msn.comTop buy-rated stocks and sell-rated stocks within Health Care - CitiApril 3, 2024 | businesswire.comInsulet to Announce First Quarter 2024 Financial Results on May 9, 2024April 3, 2024 | businesswire.comNadav Eiron Joins Crusoe as Senior Vice President of Cloud EngineeringApril 17, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.March 30, 2024 | nasdaq.comGuru Fundamental Report for PODDMarch 28, 2024 | finance.yahoo.comInvestors Will Want Insulet's (NASDAQ:PODD) Growth In ROCE To PersistMarch 28, 2024 | seekingalpha.comInsulet: Insulating Patients, Investors Still Have To WaitMarch 25, 2024 | finance.yahoo.comThe Zacks Analyst Blog Highlights Twilio, Zscaler, NextEra Energy, and American Water WorksMarch 21, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Insulet (PODD), Annovis Bio (ANVS)March 20, 2024 | msn.comInsulet names Ana Maria Chadwick as finance chiefMarch 20, 2024 | markets.businessinsider.comInsulet Names Ana Maria Chadwick CFO, Effective April 22March 20, 2024 | businesswire.comInsulet Appoints Ana Maria Chadwick as Chief Financial OfficerMarch 19, 2024 | msn.comHere's Why Insulet (PODD) Detracted in Q4March 19, 2024 | finance.yahoo.comHere’s Why Insulet (PODD) Detracted in Q4March 17, 2024 | finance.yahoo.comPODD Apr 2024 135.000 callMarch 16, 2024 | markets.businessinsider.comInsulet’s Growth Trajectory Affirmed with a Buy Rating and Revised Target PriceMarch 15, 2024 | finance.yahoo.comPODD Apr 2024 165.000 callMarch 15, 2024 | finance.yahoo.comPODD Apr 2024 190.000 putMarch 15, 2024 | finance.yahoo.comPODD Jan 2025 180.000 callMarch 11, 2024 | finance.yahoo.comCalculating The Fair Value Of Insulet Corporation (NASDAQ:PODD)March 8, 2024 | finance.yahoo.comInsulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump TherapyMarch 8, 2024 | businesswire.comInsulet's Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump TherapySee More Headlines Receive PODD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today4/17/2024Next Earnings (Confirmed)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:PODD CUSIP45784P10 CIK1145197 Webwww.insulet.com Phone(978) 600-7000Fax978-600-0120Employees3,000Year Founded2000Price Target and Rating Average Stock Price Target$243.21 High Stock Price Target$330.00 Low Stock Price Target$184.00 Potential Upside/Downside+47.0%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)$2.91 Trailing P/E Ratio56.84 Forward P/E Ratio53.70 P/E Growth3.13Net Income$206.30 million Net Margins12.16% Pretax Margin12.65% Return on Equity32.19% Return on Assets7.93% Debt Debt-to-Equity Ratio1.86 Current Ratio3.51 Quick Ratio2.62 Sales & Book Value Annual Sales$1.70 billion Price / Sales6.82 Cash Flow$3.61 per share Price / Cash Flow45.83 Book Value$10.49 per share Price / Book15.77Miscellaneous Outstanding Shares70,020,000Free Float69,462,000Market Cap$11.58 billion OptionableOptionable Beta0.98 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. James R. Hollingshead Ph.D. (Age 61)President, CEO & Director Comp: $2.18MMs. Shacey Petrovic (Age 50)Director & Advisor Comp: $2.96MMr. Eric Benjamin (Age 41)Executive VP, Chief Product & Customer Experience Officer Comp: $947.57kMs. Lauren BuddenGroup VP, Chief Accounting Officer, Controller & Interim CFO and TreasurerMr. Prem Singh (Age 47)Senior Vice President of Global Operations Mr. Mark FieldSenior VP & CTOMs. Deborah R. Gordon CPA (Age 54)Vice President of Investor Relations Mr. John Wodick Kapples (Age 64)Senior VP & General Counsel Comp: $783.36kMs. Laetitia Cousin (Age 48)Senior VP of Regulatory Affairs, Quality Assurance & Compliance Angela Geryak WiczekSenior Director of Corporate CommunicationsMore ExecutivesKey CompetitorsTeleflexNYSE:TFXGlobus MedicalNYSE:GMEDAbiomedNASDAQ:ABMDBaxter InternationalNYSE:BAXNovoCureNASDAQ:NVCRView All CompetitorsInsiders & InstitutionsPortman Square Capital LLPBought 5,000 shares on 4/15/2024Ownership: 0.000%Sunbelt Securities Inc.Bought 170 shares on 4/15/2024Ownership: 0.000%Congress Asset Management Co. MABought 9,426 shares on 4/11/2024Ownership: 0.057%Ballentine Partners LLCSold 200 shares on 4/11/2024Ownership: 0.002%Banque Cantonale VaudoiseBought 3,362 shares on 4/10/2024Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions PODD Stock Analysis - Frequently Asked Questions Should I buy or sell Insulet stock right now? 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PODD shares. View PODD analyst ratings or view top-rated stocks. What is Insulet's stock price target for 2024? 15 brokerages have issued 1 year price objectives for Insulet's stock. Their PODD share price targets range from $184.00 to $330.00. On average, they anticipate the company's stock price to reach $243.21 in the next twelve months. This suggests a possible upside of 46.3% from the stock's current price. View analysts price targets for PODD or view top-rated stocks among Wall Street analysts. How have PODD shares performed in 2024? Insulet's stock was trading at $216.98 on January 1st, 2024. Since then, PODD shares have decreased by 23.4% and is now trading at $166.26. View the best growth stocks for 2024 here. When is Insulet's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our PODD earnings forecast. How can I listen to Insulet's earnings call? Insulet will be holding an earnings conference call on Thursday, May 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Insulet's earnings last quarter? Insulet Co. (NASDAQ:PODD) announced its quarterly earnings data on Thursday, February, 22nd. The medical instruments supplier reported $1.40 EPS for the quarter, beating the consensus estimate of $0.67 by $0.73. The medical instruments supplier had revenue of $509.80 million for the quarter, compared to the consensus estimate of $461.26 million. Insulet had a net margin of 12.16% and a trailing twelve-month return on equity of 32.19%. The firm's revenue for the quarter was up 37.9% on a year-over-year basis. During the same period last year, the business posted $0.55 earnings per share. What ETFs hold Insulet's stock? ETFs with the largest weight of Insulet (NASDAQ:PODD) stock in their portfolio include Fidelity Digital Health ETF (FDHT), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Goldman Sachs Future Health Care Equity ETF (GDOC), Invesco Focused Discovery Growth ETF (IVDG), First Trust Indxx Medical Devices ETF (MDEV), Fidelity Disruptive Medicine ETF (FMED), Simplify Health Care ETF (PINK) and SPDR S&P Health Care Equipment ETF (XHE). What guidance has Insulet issued on next quarter's earnings? Insulet updated its first quarter 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $419.0 million-$429.7 million, compared to the consensus revenue estimate of $442.5 million. What is Shacey Petrovic's approval rating as Insulet's CEO? 61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Insulet own? Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD). Who are Insulet's major shareholders? Insulet's stock is owned by a number of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.43%), Portman Square Capital LLP (0.00%), Congress Asset Management Co. MA (0.06%), Banque Cantonale Vaudoise (0.01%), Moody National Bank Trust Division (0.00%) and Ballentine Partners LLC (0.00%). Insiders that own company stock include Bret Christensen, Charles Alpuche, Dan Manea, James Hollingshead, John A Fallon, Luciana Borio, Michael P Spears, Prem Singh, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan. View institutional ownership trends. How do I buy shares of Insulet? Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PODD) was last updated on 4/17/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe "Smart Money" Is Ready for May 1st Are You?Stansberry ResearchTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsOptions trading has suddenly become more reliable.Eagle Publishing[BUY ALERT] Our #1 A.I. Stock for AprilBehind the MarketsThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insulet Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.